Maryland-based Novavax signed a licensing agreement allowing Pfizer access to its technology that boosts immune responses to ...
The U.S. Food and Drug Administration approved Novavax’s COVID-19 vaccine, but limited its use to older adults and people over the age of 12 with conditions that put them at risk due to the illness.
WASHINGTON — Novavax shares surged more than 17% before the bell on Monday, following the long-delayed approval of its COVID-19 vaccine, albeit with new conditions. The Food and Drug Administration ...
The Food and Drug Administration has issued a long-awaited approval of Novavax’s COVID-19 vaccine but with unusual restrictions. Novavax makes the nation’s only traditional protein-based coronavirus ...
The Food and Drug Administration has granted full approval to Novavax, Inc. (NASDAQ:NVAX) COVID-19 vaccine, but with notable limitations. Previously available under emergency use authorization for ...
By Michael Erman and Christy Santhosh Jan 20 (Reuters) - Novavax said on Tuesday it signed a licensing agreement allowing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results